Faruqi & Faruqi, LLP is investigating the claims on behalf of investors bioage laboratory uvanja.com
Faruqi and Faruqi, Litigation Partner for LLP James (Josh) Wilson He encourages investors who have suffered losses in biogas to contact him directly to discuss their options
If you bought or acquired securities in Biota Between September 26, 2024 and January 7, 2025 And you’d like to discuss your legal rights, call your partner Faruqi and Faruqi Josh Wilson direct on 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York – (NewsFile Corp. – January 26, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioage Labs, Inc . (“Bioage” or the “Company” ) (NASDAQ: BIOA) and reminds investors of March 10, 2025 seek the role of lead plaintiff in a federal securities class action filed against the company.
Faruqi and Faruqi is a leading national law firm with offices in New York, Pennsylvania, California and Georgia. The company has taken out hundreds of millions of dollars for investors since it was founded in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the company and its executives violated federal securities laws by creating false and/or misleading information about the Phase 2 clinical trial.
Bioage completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share, which included the exercise in full by the underwriters of their option to purchase an additional 1.65 million shares.
However, less than three months later, on December 6, 2024, Bioage announced that it would stop a Phase 2 sustained-progress study of its drug candidate Azelaprag after liver transaminitis was observed in some subjects receiving Azelaprag. An analyst reported the announcement, noting that the news was surprising given that liver Tox never showed up in eight Phase 1 studies previously conducted by Bioage.
In response to the news, Bioage’s stock price decreased from $20.09 per share on December 6, 2024 to $4.65 per share on December 9, 2024.
A court-appointed lead plaintiff is the investor with the greatest financial interest in the relief sought by the class that is adequate and typical of class members directing and overseeing litigation on behalf of the purported class. Each putative class member can move the Court to serve as lead plaintiff through counsel of their choosing, or they can choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as lead plaintiff or not.
Faruqi and Faruqi, LLP also encourages anyone with information about Bioage’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.
Advertising of lawyers. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.
To view the original version of this release, visit https://www.newsfilecorp.com/release/238370
